Threshold Pharmaceuticals Inc (NASDAQ:THLD)
| 5.54 Data as of May 24 |  -0.09 / -1.60%Today’s Change | 3.95 Today|||52-Week Range 9.28 | +31.59% Year-to-Date |
Latest THLD News | Press Releases
| Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 16% May 24 / TheStreet.com |
Today’s Trading
| Previous close | 5.63 |
| Today’s open | 5.63 |
| Day’s range | 5.42 - 5.77 |
| Volume | 452,808 |
| Average volume (3 months) | 592,684 |
| Market cap | $313.3M |
| Dividend yield | -- |
Data as of 3:59pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -133.93% |
| Earnings growth (this year) | +58.30% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +9,362.90% |
| P/E ratio | 15.0 |
| Price/Sales | 38.91 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TXMDTherapeuticsMD Inc | -0.04 | -1.64% |
| RPRXRepros Therapeutics ... | +0.68 | +4.30% |
| VICLVical Inc | -0.08 | -2.23% |
| ACRXAcelRx Pharmaceutica... | +0.41 | +5.50% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.12 |
| Annual revenue (last year) | $5.9M |
| Annual profit (last year) | -$71.1M |
| Net profit margin | -1,212.46% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Harold E. Selick, PhD |
VP-Finance, Controller & Head-Investor Relations Joel A. Fernandes, CPA |
Corporate headquarters South San Francisco, California |
Forecasts
